Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Serbia: These 16 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Serbia: These 16 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Serbia?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Serbia Patent 52,408
Patent Title: FUMARATNA SO (ALFA S, BETA R)-6-BROMO-ALFA-[2-(DIMETILAMINO)ETIL]-2-METOKSI-ALFA-1-NAFTALENIL-BETA-FENIL-3-KINOLINETANOLA (FUMARATE SALT OF (ALPHA S, BETA R)-6-BROMO-ALPHA-[2-(DIMETHYLAMINO)ETHYL]-2¬METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-QUlNOLINEETHANOL)

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can AMYVID (florbetapir f-18) generic drug versions launch in Serbia?

Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: Serbia Patent 56,171

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Serbia?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Serbia Patent 56,036
Patent Title: SOLI PIPERAZINA KAO D3/D2 ANTAGONISTI (PIPERAZINE SALTS AS D3/D2 ANTAGONISTS)

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Serbia?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Serbia Patent 55,591

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Serbia?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Serbia Patent 58,248

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Serbia?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Serbia Patent 55,591

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Serbia?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Serbia Patent 58,248

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Serbia?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Serbia Patent 53,245
Patent Title: SOLI INHIBITORA JANUS KINAZE (R)-3-(4-(7H-PIROLO(2,3-D) PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CIKLOPENTILPROPAN-NITRILA (SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE)

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Serbia?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Serbia Patent 54,878
Patent Title: KRISTALNE SOLI INHIBITORA JANUS KINAZE (R)-3-(4-(7H-PIROLO[2,3-D]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CIKLOPENTILPROPIONITRIL (CRYSTALLINE SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE)

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Serbia?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Serbia Patent 58,449
Patent Title: UPOTREBA SOLI INHIBITORA JANUS KINAZE (R)-3-(4-(7H-PIROLO[2,3-D]PIRIMIDIN-4-IL)-1H- PIRAZOL-1-IL)-3-CIKLOPENTILPROPIONITRILA (USE OF SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H- PYRAZOL-1-YL)-3- CYCLOPENTYLPROPANENITRILE)

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch in Serbia?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Serbia Patent 53,638
Patent Title: KRISTALNI SOLVATI DERIVATA (1S)-1,5-ANHIDRO-1-C-(3-((FENIL) METIL) FENIL)-D-GLUCITOLA SA ALKOHOLIMA KAO INHIBITORI SGLT2 ZA TRETMAN DIJABETESA (CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)

Drug Price Trends for BYDUREON
BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. Additional details are available on the exenatide synthetic profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch in Serbia?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Serbia Patent 53,638
Patent Title: KRISTALNI SOLVATI DERIVATA (1S)-1,5-ANHIDRO-1-C-(3-((FENIL) METIL) FENIL)-D-GLUCITOLA SA ALKOHOLIMA KAO INHIBITORI SGLT2 ZA TRETMAN DIJABETESA (CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fifteen tentatively approved generics are ready to enter the market. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. Additional details are available on the dapagliflozin profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in Serbia?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Serbia Patent 53,638
Patent Title: KRISTALNI SOLVATI DERIVATA (1S)-1,5-ANHIDRO-1-C-(3-((FENIL) METIL) FENIL)-D-GLUCITOLA SA ALKOHOLIMA KAO INHIBITORI SGLT2 ZA TRETMAN DIJABETESA (CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Serbia?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Serbia Patent 54,354
Patent Title: KORTEKSOLON-17ALFA-PROPIONAT U KRISTALNOM OBLIKU I (CORTEXOLONE-17ALPHA-PROPIONATE IN CRYSTALLINE FORM I)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Serbia?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Serbia Patent 54,361
Patent Title: KORTEKSOLON-17ALFA-PROPIONAT U KRISTALNOM HIDRATNOM OBLIKU IV (CORTEXOLONE-17ALPHA-PROPIONATE IN HYDRATE CRYSTALLINE FORM IV)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Serbia?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Serbia Patent 58,950
Patent Title: FARMACEUTSKE KOMPOZICIJE KOJE SADRŽE KORTEKSOLON-17-ALFA-PROPIONAT (PHARMACEUTICAL COMPOSITIONS CONTAINING CORTEXOLONE-17-ALPHA-PROPIONATE)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in Serbia?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: Serbia Patent 55,884
Patent Title: SASTAVI, POGODNI ZA ORALNU PRIMENU KOJI SADRŽE TRIAZOL [4, 5-D]PIRIMIDIN DERIVAT (COMPOSITIONS, SUITABLE FOR ORAL ADMINISTRATION, COMPRISING A TRIAZOLO [4, 5-D]PYRIMIDIN DERIVATE)

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Serbia?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Serbia Patent 53,588
Patent Title: JEDINJENJA I KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZA (COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS)

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Serbia?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Serbia Patent 53,569
Patent Title: NOVA JEDINJENJA I KOMPOZICIJE, TE POSTUPCI ZA UPOTREBU (NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE)

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Serbia?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Serbia Patent 53,569
Patent Title: NOVA JEDINJENJA I KOMPOZICIJE, TE POSTUPCI ZA UPOTREBU (NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE)

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Serbia?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: Serbia Patent 56,045
Patent Title: DERIVATI SUPSTITUISANOG 2,3-DIHIDROIMIDAZO[1,2-C]HINAZOLINA KOJI SU KORISNI ZA TRETMAN HIPER-PROLIFERATIVNIH POREMEĆAJA I BOLESTI POVEZANIH SA ANGIOGENEZOM (SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS)

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Serbia?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Serbia Patent 61,765
Patent Title: REŽIM DOZIRANJA POVEZAN SA DUGODELUJUĆIM INJEKTABILNIM ESTRIMA PALIPERIDONA (DOSING REGIMEN ASSOCIATED WITH LONG ACTING INJECTABLE PALIPERIDONE ESTERS)

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

Serbia Branded and Generic Drug Market: Regulatory Opportunities, Patent Risk, and Commercial Outlook

Last updated: October 10, 2026

Serbia is a price-sensitive, reimbursement-driven pharmaceutical market with strong generic penetration and a growing role as a regional manufacturing and distribution base. The main commercial opportunities are in generic substitution, hospital medicines, biosimilars, complex formulations, and local production. The main risks are public procurement pricing, delayed reimbursement access, currency exposure, regulatory workload, limited market size, and the absence of an EU-wide approval mechanism.

Serbia is not an EU member. Marketing authorization, pricing, reimbursement, pharmacovigilance, and patent enforcement therefore remain nationally controlled, although Serbia’s legislation is progressively aligned with EU pharmaceutical rules.

What is the size and structure of the Serbian pharmaceutical market?

Serbia’s market is divided between reimbursed medicines supplied through the Republic Health Insurance Fund, or RFZO, and private-market medicines sold through community pharmacies and hospitals.

Market segment Main buyer or access channel Commercial characteristics
RFZO-reimbursed medicines National and institutional procurement Price-sensitive, tender-driven, dependent on reimbursement listing
Prescription private market Pharmacies and patients Brand recognition and physician prescribing influence demand
Hospital medicines Public hospitals and centralized procurement Concentrated purchasing, technical specifications and price competition
OTC medicines Retail pharmacies and consumer purchases Brand, distribution and marketing are important
Imported specialty medicines Hospital and specialist channels Regulatory, budget and tender access are decisive
Biosimilars Hospitals and specialist prescribing Increasing opportunity, but substitution and procurement rules matter

The market is smaller than those of Central European EU states, but Serbia has strategic importance because it can support regional operations across the Western Balkans. Pharmaceutical companies commonly evaluate Serbia together with Bosnia and Herzegovina, Montenegro, North Macedonia, Albania and Kosovo, although each jurisdiction has separate approval, reimbursement and procurement rules.

Local production is significant. Hemofarm, part of STADA Arzneimittel, is one of the most important Serbian manufacturers. Galenika is another established domestic producer. Krka, Sandoz, Teva, Roche, Novartis, Pfizer, Bayer, Sanofi and other international companies participate through subsidiaries, distributors, local partners or direct commercial operations.

Which companies compete in Serbia’s branded and generic drug markets?

Serbia has a mixed competitive model.

Local and regional generic manufacturers

Domestic and regional manufacturers compete aggressively in established molecules, hospital products, OTC medicines and tendered products. Their advantages include:

  • Existing relationships with wholesalers, pharmacies and hospitals
  • Familiarity with RFZO procurement procedures
  • Lower manufacturing and distribution costs
  • Local-language regulatory and pharmacovigilance infrastructure
  • Ability to supply small or medium-volume products that multinational companies may deprioritize

Hemofarm has the strongest international manufacturing profile among Serbian-origin producers because of its STADA ownership and export network. Galenika has a broad consumer and prescription portfolio and remains important in domestic distribution.

Multinational originator companies

Originator companies retain value in oncology, immunology, rare diseases, vaccines, diabetes, cardiology and specialty hospital products. Their market access depends less on retail brand recognition than on:

  • Inclusion in RFZO reimbursement schedules
  • Hospital tender success
  • Health-technology assessment evidence
  • Budget impact
  • Clinical guideline positioning
  • Local medical-affairs coverage

A branded product can remain commercially relevant after patent expiry if it has a strong physician base, a trusted safety profile, supply reliability or a complex formulation that generic competitors cannot easily replicate.

Generic and biosimilar entrants

Generic competition is strongest where:

  • The active ingredient is chemically simple
  • Several suppliers have approval
  • RFZO procurement uses price as a major award criterion
  • The product has no meaningful device, formulation or manufacturing barrier
  • The reference product has lost effective exclusivity

Biosimilar competition is more selective. It is most relevant in oncology, hematology, endocrinology and autoimmune treatment. Regulatory approval alone does not guarantee rapid uptake because prescribing, interchangeability, hospital protocols and procurement decisions can determine whether a biosimilar gains volume.

What regulatory authority approves medicines in Serbia?

The Medicines and Medical Devices Agency of Serbia, known as ALIMS, is responsible for core medicinal-product regulation. Its functions include:

  • Marketing authorization
  • Variations and renewals
  • Clinical-trial oversight
  • Pharmacovigilance
  • Good manufacturing practice and related inspections
  • Product information review
  • Import and distribution oversight
  • Safety communications and recalls

Serbia does not participate in the EU centralized authorization system as a member state. An EU centralized marketing authorization does not automatically provide a Serbian authorization. Companies must manage a Serbian regulatory pathway, local representation and Serbian-language product information.

The Serbian framework is based principally on the Law on Medicines and Medical Devices and associated regulations. EU directives and guidelines are important reference points, but Serbian law controls the domestic authorization and market-access process.[1][2]

What are the main regulatory opportunities?

The clearest opportunities are:

  1. Registration of established generics with reliable supply and competitive pricing.
  2. Biosimilar entry in high-cost hospital categories.
  3. Local or regional manufacturing partnerships.
  4. Contract manufacturing and technology-transfer arrangements.
  5. Specialty medicines supported by strong reimbursement dossiers.
  6. OTC switches and consumer-health products.
  7. Products that reduce hospital administration costs or improve adherence.
  8. Supply agreements for RFZO and hospital tenders.

Serbia can also support a Western Balkans launch strategy when regulatory documentation, artwork, pharmacovigilance systems and supply-chain controls are designed for reuse across neighboring markets.

What are the main regulatory challenges?

Companies face several operational constraints:

  • Serbian-language dossiers, labeling and patient information
  • Separate national submissions and lifecycle management
  • Local pharmacovigilance obligations
  • Variable administrative timing
  • Reimbursement and authorization processes that are not synchronized
  • Tender-driven price compression
  • Import, batch-release and supply continuity requirements
  • Limited commercial scale for products requiring large field forces
  • Need for local regulatory and market-access capabilities

The most common strategic error is treating Serbian registration as equivalent to EU approval. It is not. EU data, certificates and assessments can support a Serbian application, but the Serbian authorization process remains distinct.

What patents protect drugs in Serbia?

Serbian patents generally have a 20-year term from the filing date, subject to payment of maintenance fees. Pharmaceutical inventions may also qualify for a supplementary protection certificate, or SPC, where statutory requirements are satisfied. The SPC can extend protection for an authorized medicinal product for up to five years, with a possible additional six-month pediatric extension under EU-aligned conditions.[3]

Patent protection may cover:

  • The active pharmaceutical ingredient
  • Salts, polymorphs and crystalline forms
  • Enantiomers and stereoisomers
  • Formulations and excipients
  • Dosage regimens
  • Combination therapies
  • Manufacturing processes
  • Medical uses
  • Drug-delivery devices
  • Diagnostic or patient-selection methods linked to treatment

Patent strength depends on claim scope, validity, prosecution history, enablement, inventive step and the evidence available to support infringement.

What formulation patents are important in Serbia?

Formulation patents can be more commercially important than compound patents after the basic molecule expires. They may protect:

  • Extended-release tablets
  • Enteric-coated products
  • Long-acting injectable formulations
  • Depot systems
  • Fixed-dose combinations
  • Stabilized biologic formulations
  • Device-cartridge combinations
  • Specific particle sizes or polymorphs

A generic company may avoid a formulation patent by using a different excipient system, release mechanism or dosage form. That strategy requires technical development and may produce a product with a narrower commercial position than the originator.

How are method-of-use patents enforced?

Serbian law can protect new therapeutic uses and treatment regimens, but enforcement depends on claim wording and the available infringement evidence. Method-of-use patents are harder to enforce where a generic label omits the patented indication and the product is capable of substantial non-infringing use.

Originators should monitor:

  • Approved indications
  • Serbian product information
  • Physician and hospital promotion
  • Tender specifications
  • Distribution patterns
  • Substitution and prescribing data
  • Generic labeling and promotional materials

Does Serbia have an Orange Book or Paragraph IV system?

Serbia does not have a direct equivalent to the U.S. FDA Orange Book or the U.S. Hatch-Waxman Paragraph IV certification system.

There is no single Serbian publication that functions as the definitive public register of all patents relevant to every approved medicine. Patent analysis normally requires combining:

  • Serbian Intellectual Property Office records
  • European Patent Office records
  • National patent validations
  • SPC records
  • ALIMS authorization information
  • Published product information
  • Court and procurement records
  • Originator and generic regulatory disclosures

A Serbian generic applicant does not follow the U.S. Paragraph IV process by certifying that a listed patent is invalid or will not be infringed. The applicant instead assesses patent risk under Serbian patent law and may face infringement litigation if it launches before relevant rights expire.

What does this mean for generic launch timing?

Generic entry should be modeled against several separate dates:

Date or event Commercial relevance
Basic compound patent expiry May permit entry if no other blocking rights exist
SPC expiry Can delay launch beyond the patent term
Data or market exclusivity expiry May determine when reliance on reference-product data is available
Formulation patent expiry May restrict a particular dosage form
Method-of-use patent expiry May restrict specific indications
Regulatory approval Does not eliminate patent infringement risk
Reimbursement listing Determines practical access to public demand
Procurement award Determines actual sales volume

A Serbian authorization does not provide a safe harbor against patent infringement. Regulatory approval and patent freedom to operate are separate questions.

When do branded drugs lose exclusivity in Serbia?

There is no single exclusivity date applicable to all products. The practical loss of exclusivity occurs when the relevant regulatory protection ends, the relevant patents and SPCs expire, and a competitor secures approval and commercial access.

Serbia has been moving toward EU-style regulatory data and market protection. The applicable protection period must be checked against the law and transitional provisions in force when the reference product was authorized. Patent and regulatory exclusivity should therefore be analyzed separately.

For each branded product, companies should create an exclusivity calendar covering:

  • Serbian marketing-authorization date
  • Reference-product status
  • Data-protection period
  • Market-exclusivity period
  • Pediatric extension
  • Basic patent expiry
  • SPC expiry
  • Formulation and use-patent expiry
  • Expected generic approval date
  • RFZO reimbursement and tender timing

Which companies are challenging branded products in Serbia?

Public information on Serbian patent challenges is less transparent than in the United States. Serbia does not maintain a comprehensive public Paragraph IV database, and many commercial challenges appear through regulatory filings, procurement activity or court proceedings rather than a centralized challenge notice.

The most likely challengers are established generic companies with:

  • Existing Serbian registration infrastructure
  • Regional production capacity
  • A portfolio in the relevant therapeutic area
  • Access to RFZO or hospital tenders
  • Technical capability to design around formulation or process claims

A company assessing challenge risk should examine Serbian and European patent families together. A Serbian patent may be validated from a European patent, while related patents may have different claim scope or expiry dates in Serbia.

What patent litigation and settlement risks affect Serbia?

Patent disputes may involve:

  • Infringement actions
  • Invalidity claims
  • Preliminary injunctions
  • Customs or border measures
  • Appeals concerning patent validity
  • Disputes over manufacturing for export
  • Distribution or tender participation
  • Contractual disputes between licensees and distributors

Settlement agreements can control launch dates, authorized supply arrangements or geographic rights. Their commercial terms are not always publicly available. Unlike the U.S., Serbia does not have a standard Federal Trade Commission review process that produces a public record for every pharmaceutical patent settlement.

An originator considering litigation must weigh the value of Serbian sales against enforcement cost, launch timing, evidence quality and the risk that a competitor designs around the asserted claims.

What is the Serbian reimbursement and procurement environment?

RFZO reimbursement is the central market-access issue for prescription medicines. A product can be fully authorized but commercially limited if it is not reimbursed or not selected in public procurement.

Market-access submissions generally need to address:

  • Clinical benefit
  • Comparator choice
  • Budget impact
  • Patient population
  • Treatment cost
  • Supply reliability
  • Pharmacoeconomic rationale
  • Local pricing and reference-country effects

Public procurement creates substantial price pressure. A company may obtain approval but fail to generate meaningful revenue if it lacks tender competitiveness or cannot maintain supply at the awarded price.

The commercial risk is highest for products with:

  • Multiple generic suppliers
  • Low clinical differentiation
  • High tender concentration
  • Limited private-pay demand
  • Significant cold-chain or import costs
  • Small patient populations without protected reimbursement

What licensing and manufacturing opportunities exist in Serbia?

Serbia offers opportunities for:

  • Contract manufacturing
  • Secondary packaging
  • Technology transfer
  • Regional supply agreements
  • Local distribution partnerships
  • In-licensing of established generics
  • Co-development of biosimilars and complex injectables
  • Manufacturing for export to neighboring markets

The strongest opportunities involve products where local production reduces landed cost or improves tender reliability. Manufacturing arrangements must address GMP compliance, batch release, quality agreements, pharmacovigilance, serialization, recalls, technology ownership and change-control rights.

Licensing agreements should define Serbian territory separately from the broader Western Balkans. A Serbian license does not automatically cover Montenegro, Bosnia and Herzegovina, North Macedonia or Albania.

How does Serbia compare with EU markets?

Issue Serbia EU member state
Marketing authorization National ALIMS process National or EU centralized/decentralized routes
Patent system National rights and validations EU member-state rights, with European and unitary systems where applicable
Reimbursement RFZO and national institutions National payer and HTA systems
Orange Book No direct equivalent No single EU-wide Orange Book
Paragraph IV No U.S.-style system National procedures vary
Procurement Strong public-tender influence Varies by member state
Market size Smaller Generally larger in aggregate
Regional launch value High for Western Balkans Higher integration within EU supply chains
Regulatory complexity National plus EU-alignment requirements EU framework with national implementation

Serbia can be easier to enter than heavily regulated EU markets in some products because of its smaller scale and established local-partner model. It can also be harder to manage because national approval, reimbursement and procurement must be handled separately from EU procedures.

What revenue exposure and generic launch scenarios should companies model?

Revenue exposure should be assessed by product rather than by country average. The highest-value products are usually specialty medicines, hospital biologics, oncology products and chronic therapies with large reimbursed patient populations.

A practical scenario model is:

Scenario Main condition Expected commercial result
Protected launch Valid patent or SPC remains in force Originator retains primary market access
First generic entry One approved competitor with tender access Rapid price reduction and share loss risk
Multi-generic entry Several competitors launch Severe price compression
Design-around entry Generic avoids formulation or use patent Partial erosion of originator volume
Biosimilar substitution Multiple biosimilars and institutional procurement Significant hospital share shift
Delayed reimbursement Approval obtained but listing delayed Limited near-term revenue
Supply-constrained market Few reliable suppliers Higher value for dependable manufacturers

Key Takeaways

  • Serbia is a generic-heavy, reimbursement-dependent market with meaningful local manufacturing capacity.
  • ALIMS authorization is separate from EU authorization and does not remove Serbian patent risk.
  • There is no Serbian equivalent to the U.S. Orange Book or Paragraph IV system.
  • Patent analysis should cover compound, SPC, formulation, process, combination and method-of-use rights.
  • RFZO reimbursement and hospital procurement often determine commercial success more than marketing authorization.
  • Generic and biosimilar opportunities are strongest in high-volume or high-cost reimbursed categories.
  • Local manufacturing, contract production and regional licensing are credible growth strategies.
  • Patent litigation and settlement data are less transparent than in the United States.
  • The most important commercial dates are patent expiry, SPC expiry, regulatory exclusivity expiry, approval, reimbursement listing and tender award.
  • Serbia is commercially attractive as a Western Balkans platform, but each neighboring market requires separate regulatory and reimbursement planning.

FAQs About Serbia’s Pharmaceutical Market and Drug Patent Rules

Is Serbia part of the European Medicines Agency system?

No. Serbia is not an EU member and does not receive automatic marketing authorization through the EMA. Serbian authorization through ALIMS remains necessary.

Can a generic launch in Serbia before a Serbian patent expires?

A generic may be approved or developed in circumstances permitted by regulatory and patent law, but commercial launch before patent expiry creates potential infringement risk. Regulatory approval does not establish freedom to operate.

Are biosimilars automatically interchangeable in Serbia?

No automatic assumption should be made. Interchangeability and substitution depend on Serbian regulatory, prescribing, institutional and reimbursement practice.

Does a Serbian patent cover the entire Western Balkans?

No. Patent rights are territorial. A Serbian patent generally does not provide protection in Montenegro, Bosnia and Herzegovina, North Macedonia, Albania or Kosovo.

Are pharmaceutical patent settlements publicly disclosed in Serbia?

Not consistently. Settlement terms may remain confidential, and public information may be limited to court records, procurement activity, regulatory documents or company disclosures.

References

  1. Medicines and Medical Devices Agency of Serbia. (n.d.). ALIMS: Medicines and medical devices regulatory framework. https://www.alims.gov.rs/

  2. Republic of Serbia. (2017). Law on Medicines and Medical Devices. Official Gazette of the Republic of Serbia.

  3. Intellectual Property Office of the Republic of Serbia. (n.d.). Patent protection and supplementary protection certificates. https://www.zis.gov.rs/

  4. Republic Health Insurance Fund of Serbia. (n.d.). Medicines covered by compulsory health insurance and procurement information. https://www.rfzo.rs/

  5. European Patent Office. (n.d.). European patent validation and SPC framework. https://www.epo.org/

  6. European Commission. (2024). Serbia 2024 report: Pharmaceutical regulation, health policy and EU accession assessment. European Commission.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.